PS 14-35 INFLUENCE OF AZILSARTAN MEDOXOMIL ON CENTRAL AORTIC BLOOD PRESSURE AND AMBULATORY BLOOD PRESSURE IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION

    loading  Checking for direct PDF access through Ovid

Abstract

Objective:

This study was planned to assess influence of azilsartan medoxomil (AZL) on central aortic blood pressure (CAP) and 24-hours blood pressure (BP) in patients with mild to moderate hypertension.

Design and Method:

Twenty-nine patients (75% men, all white, mean age – 43 years) with mild to moderate essential hypertension, never treated before, were enrolled. Dose of AZL was gradually increased until maximum 80 mg once-daily. Follow-up of the study amounted to 6 months. CAP measurement (SphygmoCor CVMS, Atcor, Australia) and 24-hours blood pressure monitoring (ABPM, Meditech, Hungary) were measured before treatment and on the last visit.

Results:

Mean value (mean ± SEM) of baseline 24-hours systolic BP (SBP) was 144 ± 1.8 mmHg and 24-hours diastolic BP (DBP)–85 ± 1.6 mmHg, while mean value of CAP was 139 ± 2.9 mmHg. At the end of the study mean value of 24-hours SBP was 128 ± 1.9 mmHg, 24-hours DBP–77 ± 2.1 mmHg and CAP was 121 ± 3,0 mmHg. So decrease from baseline to final CAP, 24-hours SBP and 24-hours DBP were −18, −16 and −8 mmHg respectively. An outcome of the study shows a significant reduction in both 24-hours SBP and DBP (p < 0.0001) and CAP changes (p < 0.005).

Conclusions:

Once-daily AZL effectively lowers CAP in adults with mild to moderate essential hypertension and has shown good antihypertensive efficacy according to 24-hours blood pressure monitoring as well.

Related Topics

    loading  Loading Related Articles